Tradestie Institutional Equity Comparison Engine

CNTB vs UNCY โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

UNCY Overall Edge

UNCY Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Unicycive Therapeutics, Inc. Common Stock (UNCY) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CNTB counters with relative strength in Valuation. Fundamentally, CNTB trades at 0.8x Forward P/E with -2384.5% operating margin (+5666.7% YoY revenue) versus UNCY at 2.5x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CNTB sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against UNCY sits in BREAKDOWN (30th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CNTB
CNTB 0.8x vs UNCY 2.5x Fwd P/E
Growth & Margin Winner UNCY
Op Margin -2384.5% vs 0.0% ยท YoY +5666.7% vs +0.0%
Momentum & Technical Winner UNCY
1Y -71.2% vs -34.3% ยท 52W Pos 2% vs 7%
Options & Structure Winner UNCY
UNCLASSIFIED (100th %ile IV) vs BREAKDOWN (30th %ile IV)
CNTB NASDAQ
Connect Biopharma Holdings Limited Ordinary Shares
Pharmaceutical Preparations
$0.61
-5.07% 1D
Market Cap $42.6M
1M Return -32.16%
1Y Return -71.21%
Forward P/E 0.8x
Unified AI Score
41.0 / 100 SELL
Tech 25.0 Fund 48.0 Flow 66.0 Mom 55.0
UNCY NASDAQ
Unicycive Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.73
+0.68% 1D
Market Cap $97.2M
1M Return +6.13%
1Y Return -34.3%
Forward P/E 2.5x
Unified AI Score
43.7 / 100 HOLD
Tech 30.0 Fund 50.0 Flow 70.0 Mom 58.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CNTB -71.21% UNCY -34.3% Spread: +36.91 pp (UNCY Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CNTB Revenue UNCY Revenue CNTB Op. Margin UNCY Op. Margin Margin Edge
FY2022 N/A $0M N/A -1898.2% UNCY
FY2023 N/A $0M N/A -3077.6% UNCY
FY2024 $30M N/A -86.2% N/A CNTB
FY2025 $0M N/A -90740.6% N/A CNTB

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CNTB (3) vs UNCY (6)
Institutional Metric CNTB UNCY Criterion Row Winner
Market Capitalization Scale $42.6M $97.2M Larger Scale UNCY
Trailing P/E Ratio Valuation 0.8x 2.0x Lower Multiple CNTB
Forward P/E Ratio Valuation 0.8x 2.5x Lower Multiple CNTB
Revenue Growth (YoY) Growth +5666.7% +0.0% Higher Growth CNTB
Operating Margin (TTM) Profitability -2384.5% 0.0% Higher Margin UNCY
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -140.5% -101.1% Higher ROE UNCY
52-Week Range Position Momentum 2% ($1โ€“$4) 7% ($3โ€“$9) Stronger Trend UNCY
Beta / 30D Volatility Risk Regime 0.92ฮฒ ยท 68% Vol 1.02ฮฒ ยท 66% Vol Lower Realized Risk UNCY
Unified Institutional Score Composite Signal 41.0 / 100 (SELL) 43.7 / 100 (HOLD) Higher Composite UNCY

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CNTB vs UNCY Buy Guide
CNTB UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live CNTB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
UNCY BREAKDOWN
129d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 30th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live UNCY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CNTB nor UNCY registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.